Source: Annual Congress 2004 - Management of infection and tuberculous diseases II
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Z. Kilicaslan, F. Ozturk, N. Sarimurat, S. Kumbetli, C. Kucuk, D. Polat, E. Pekdemir (Istanbul, Turkey). Success of re-treatment regime and influencing factors in patients with tuberculosis. Eur Respir J 2004; 24: Suppl. 48, 3969

Member's Comments

No comment yet.

Related content which might interest you: Risk factors in tuberculosis and its influence on chemotherapy efficiency Source: Eur Respir J 2005; 26: Suppl. 49, 649s Year: 2005 Factors preventing better treatment completion among MDR TB cases in a rich-resource setting Source: Annual Congress 2010 - Emerging drug resistance in tuberculosis Year: 2010 Influence of social adaptation of tuberculosis patients on the TB form and a chemotherapy outcomes Source: Annual Congress 2012 - Tuberculous and non-tuberculous mycobacterial infections: epidemiology I Year: 2012 Treatment interruptions in patients with MDR/XDR-TB: risk factors and impact on treatment outcomes Source: International Congress 2016 – Drug-resistant tuberculosis and experiences with delamanid and bedaquiline Year: 2016 Study of risk factors in relapses at patients with pulmonary tuberculosis. Their retreatment results Source: Eur Respir J 2001; 18: Suppl. 33, 467s Year: 2001 Factors affecting the efficacy of treatment of MDR/XDR TB patients receiving bedaquiline Source: International Congress 2019 – Tuberculosis: a public health approach Year: 2019 Risk factors for paradoxical response during adequate tuberculosis treatment Source: Eur Respir J 2005; 26: Suppl. 49, 649s Year: 2005 Factors affecting tuberculosis treatment: the beliefs of patients Source: Eur Respir J 2005; 26: Suppl. 49, 649s Year: 2005 Risk Factors for tuberculosis in patients on anti-TNF treatment Source: International Congress 2019 – Tuberculosis and comorbidities Year: 2019 Risk factors associated with treatment interruption for 2 months among tuberculosis patients in Taipei Source: Annual Congress 2007 - Tuberculosis control Year: 2007 Risk factors for relapses of tuberculosis Source: Eur Respir J 2003; 22: Suppl. 45, 345s Year: 2003 Factors affecting outcomes of individualised treatment for drug resistant tuberculosis in an endemic region> Source: International Congress 2017 – TB: co-morbidities and outcome Year: 2017 Impact of pre-treatment duration by first line drugs on treatment outcomes of patients with MDR-TB Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 Factors associated with completion of tuberculosis treatment Source: Eur Respir J 2005; 26: Suppl. 49, 428s Year: 2005 Reevaluation of treatment outcome of relapse and defaulter pulmonary tuberculosis cases Source: Eur Respir J 2004; 24: Suppl. 48, 650s Year: 2004 The characteristics of previous tuberculosis treatment programmes in patients with tuberculosis relapses Source: Eur Respir J 2001; 18: Suppl. 33, 473s Year: 2001 Could side effects of MDR-TB treatment change the outcome of the disease? Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015 A choice of regimen improves completion for patients with latent TB infection Source: Breathe 2008; 4: 366 Year: 2008 Impact of XDR-TB on treatment outcome of MDR-TB patients with standardized regimens Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis Year: 2008 Treatment effectiveness and predictors of poor outcome in MDR-TB and XDR-TB Source: Breathe 2008; 6: 161 Year: 2009